Defining the benefits of neoadjuvant chemotherapy for breast cancer

Journal of Clinical Oncology

Volumn 30, Issue 15, 2012, Pages 1747-1749

  Schott, Anne F ^a   Hayes, Daniel F ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; BREAST CANCER; EDITORIAL; HUMAN; MASTECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PATIENT CARE; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SURGICAL APPROACH; TRIPLE NEGATIVE BREAST CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; MASTECTOMY; NEOADJUVANT THERAPY;

EID: 84864012459     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.41.3161     Document Type: Editorial

References (29)

1. Edwards T: Dictionary of Thoughts. Detroit, MI, F. B. Dickerson Company, 1908, p 88
2. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998 (Pubitemid 28363030)
3. van der Hage JA, van de Velde CJ, Julien JP, et al: Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19:4224-4237, 2001
4. Hortobagyi GN, Ames FC, Buzdar AU, et al: Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62:2507-2516, 1988 (Pubitemid 19006431)
5. Danforth DN Jr, Lippman ME, McDonald H, et al: Effect of preoperative chemotherapy on mastectomy for locally advanced breast cancer. Am Surg 56:6-11, 1990 (Pubitemid 20132037)
6. Schwartz GF, Birchansky CA, Komarnicky LT, et al: Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 73:362-369, 1994 (Pubitemid 24030615)
7. Semiglazov V, Eiermann W, Zambetti M, et al: Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study. Eur J Surg Oncol 37:856-863, 2011
8. Fisher B, Brown A, Mamounas E, et al: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483-2493, 1997 (Pubitemid 27289876)
9. Oh JL, Dryden MJ, Woodward WA, et al: Locoregional control of clinically diagnosed multifocal or multicentric breast cancer after neoadjuvant chemotherapy and locoregional therapy. J Clin Oncol 24:4971-4975, 2006 (Pubitemid 46631398)
10. Morrow M, Jagsi R, Alderman AK, et al: Surgeon recommendations and receipt of mastectomy for treatment of breast cancer. JAMA 302:1551-1556, 2009
11. Schott AF, Roubidoux MA, Helvie MA, et al: Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat 92:231-238, 2005 (Pubitemid 41282819)
12. Thomas E, Holmes FA, Smith TL, et al: The use of alternate, non-crossresistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: Long-term results from a prospective randomized trial. J Clin Oncol 22:2294-2302, 2004 (Pubitemid 41115385)
13. von Minckwitz G, Kümmel S, Vogel P, et al: Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: Phase III randomized GeparTrio trial. J Natl Cancer Inst 100:542-551, 2008
14. Wesolowski R, Budd GT: Neoadjuvant therapy for breast cancer: Assessing treatment progress and managing poor responders. Current Oncol Repo 11:37-44, 2009
15. Gralow JR, Burstein HJ, Wood W, et al: Preoperative therapy in invasive breast cancer: Pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 26:814-819, 2008 (Pubitemid 351265335)
16. Mazouni C, Peintinger F, Wan-Kau S, et al: Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol 25:2650-2655, 2007 (Pubitemid 47123169)
17. Symmans WF, Peintinger F, Hatzis C, et al: Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414-4422, 2007 (Pubitemid 350013847)
18. Rouzier R, Extra JM, Klijanienko J, et al: Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 20:1304-1310, 2002 (Pubitemid 34177437)
19. von Minckwitz G, Untch M, Blohmer J-U, et al: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30:1796-1804, 2012
20. Wolff AC, Berry D, Carey LA, et al: Research issues affecting preoperative systemic therapy for operable breast cancer. J Clin Oncol 26:806-813, 2008 (Pubitemid 351264394)
21. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Comparisons between different polychemotherapy regimens for early breast cancer: Meta-analyses of long-term outcome among 100,000 women in 123 randomized trials. Lancet 379:432-444, 2012
22. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005 (Pubitemid 41464706)
23. Bear HD, Anderson S, Smith RE, et al: Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24:2019-2027, 2006 (Pubitemid 46622110)
24. Buzdar AU, Ibrahim NK, Francis D, et al: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23:3676-3685, 2005
25. SWOG: SWOG 0800: A randomized phase II trial of weekly nanoparticle albumin bound paclitaxel (nab-paclitaxel) (NSC-736631) with or without bevacizumab, either preceded by or followed by Q 2 week doxorubicin (A) and cyclophosphamide (C) plus pegfilgrastim (Peg-G) as neoadjuvant therapy for inflammatory and locally advanced HER-2/neu negative breast cancer. http://www.swog.org/visitors/ViewProtocolDetails.asp?ProtocolID=2147
26. ClinicalTrials.gov: CALGB 40603: Randomized phase II 2 × 2 factorial trial of the addition of carboplatin ± bevacizumab to neoadjuvant weekly paclitaxel followed by dose-dense AC in hormone receptor-poor/Her2-negative resectable breast cancer. http://clinicaltrials.gov/ ct2/show/NCT00861705
27. ClinicalTrials.gov: NSABP B40: A randomized phase III trial of neoadjuvant therapy in patients with palpable and operable breast cancer evaluating the effect on pathologic complete response (pCR) of adding capecitabine or gemcitabine to docetaxel when administered before AC with or without bevacizumab and correlative science studies attempting to identify predictors of high likelihood for pCR with each of the regimens. http://clinicaltrials.gov/ct2/show/NCT00408408?term=NSABP+B40&rank=1
28. Barker AD, Sigman CC, Kelloff GJ, et al: I-SPY 2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 86:97-100, 2009
29. Albain KS, Barlow WE, Ravdin PM, et al: Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: A phase 3, open-label, randomised controlled trial. Lancet 374:2055-2063, 2009